CN110559436A - Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases - Google Patents
Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases Download PDFInfo
- Publication number
- CN110559436A CN110559436A CN201910819357.5A CN201910819357A CN110559436A CN 110559436 A CN110559436 A CN 110559436A CN 201910819357 A CN201910819357 A CN 201910819357A CN 110559436 A CN110559436 A CN 110559436A
- Authority
- CN
- China
- Prior art keywords
- yolk antibody
- helicobacter pylori
- egg yolk
- yolk
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 178
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims description 13
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 110
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 107
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 45
- 102000002322 Egg Proteins Human genes 0.000 claims description 41
- 108010000912 Egg Proteins Proteins 0.000 claims description 41
- 235000013345 egg yolk Nutrition 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 40
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 30
- 241000894006 Bacteria Species 0.000 claims description 30
- 235000013336 milk Nutrition 0.000 claims description 28
- 239000008267 milk Substances 0.000 claims description 28
- 210000004080 milk Anatomy 0.000 claims description 28
- 101710116435 Outer membrane protein Proteins 0.000 claims description 25
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 23
- 206010017758 gastric cancer Diseases 0.000 claims description 23
- 201000011549 stomach cancer Diseases 0.000 claims description 23
- 208000007882 Gastritis Diseases 0.000 claims description 21
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 108091005804 Peptidases Proteins 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 16
- 229910021529 ammonia Inorganic materials 0.000 claims description 15
- 235000013312 flour Nutrition 0.000 claims description 15
- 235000007164 Oryza sativa Nutrition 0.000 claims description 11
- 235000009566 rice Nutrition 0.000 claims description 11
- 230000003053 immunization Effects 0.000 claims description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 8
- 235000013350 formula milk Nutrition 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 235000013601 eggs Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 201000005917 gastric ulcer Diseases 0.000 description 18
- 210000001035 gastrointestinal tract Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 241000209094 Oryza Species 0.000 description 10
- 241001122767 Theaceae Species 0.000 description 10
- 239000002131 composite material Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000000746 purification Methods 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000013329 compounding Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091005508 Acid proteases Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 108010071023 Bacterial Outer Membrane Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020604 functional milk Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides a yolk antibody composition and application thereof in preparing products for preventing and treating gastrointestinal diseases. The invention compounds the four yolk antibodies, the combination potency of the obtained compound yolk antibody and helicobacter pylori is far higher than that of any single yolk antibody, the invention has obvious effect of resisting helicobacter pylori infection, and the invention can be further applied to various products, and can effectively prevent and treat related diseases caused by helicobacter pylori infection.
Description
Technical Field
The invention relates to the technical field of biology, in particular to an egg yolk antibody composition and application thereof in preparing products for preventing and treating gastrointestinal diseases.
Background
Helicobacter pylori (Helicobacter pylori) was discovered by scientists Barry Marshall and Robin Warren, who were able to infect stomach tissue and cause ulcers, and it is estimated that half of the world population is infected with Helicobacter pylori. Moreover, the infection with H.pylori usually occurs in the young stage, and the bacterium is widespread, and many people are carriers of the bacterium and may cause the infection with H.pylori at some point in life. So that the human body is possibly suffered from stomach diseases such as gastritis, gastric ulcer and even gastric cancer. Helicobacter pylori is also a causative agent of gastric cancer, and the main cause of gastric cancer is considered to be helicobacter pylori infection.
at present, no effective treatment method for gastrointestinal diseases such as gastric cancer exists, and helicobacter pylori is generally treated by taking various antibiotics with large dose. However, not only does this approach kill a large number of beneficial bacteria, but the continued spread of antibiotic resistance makes treatment of such bacterial infections more complicated. In the prior art, the curative effect of helicobacter pylori infection prevention medicines is poor, and urgent solution is needed.
In addition, nowadays, the living standard of people is improved, the requirement on living quality is higher, the requirement on ensuring the health level of children is higher, and the infection of helicobacter pylori often occurs in the infant stage, so that the use of antibiotics for infants is more cautious. Therefore, the invention discloses a safer and more efficient helicobacter pylori resistant product which is necessary for preventing and treating gastrointestinal diseases such as gastritis, gastric ulcer, gastric cancer and the like, in particular for preventing and treating helicobacter pylori infection of infants and teenagers.
Disclosure of Invention
The invention aims to overcome the defects and shortcomings of the prior art and meet the increasing living health level requirements of people in the current society, and the first purpose is to provide the yolk antibody composition for resisting helicobacter pylori, which can be applied to the prevention and treatment of gastrointestinal tract diseases caused by helicobacter pylori infection, such as gastritis, gastric ulcer, gastric cancer and the like, is efficient and safe, and can be applied to food to realize the purpose of preventing helicobacter pylori infection.
The above purpose of the invention is realized by the following technical scheme:
The invention provides an egg yolk antibody composition, which comprises the following components: h.pylori hypha ammonia protease egg yolk antibody, H.pylori outer membrane protein egg yolk antibody, H.pylori whole bacteria egg yolk antibody and H.pylori broken bacteria egg yolk antibody.
The invention compounds four yolk antibodies which can effectively prevent and treat stomach problems caused by helicobacter pylori infection, namely, helicobacter pylori mycelium ammonia protease yolk antibody, helicobacter pylori outer membrane protein yolk antibody, helicobacter pylori whole-cell yolk antibody and helicobacter pylori broken-cell yolk antibody, and prepares special functional products which can be used for solving gastrointestinal tract diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection. The excellent functional product preparation can not only block the infection of helicobacter pylori to human body, but also effectively prevent and treat diseases related to the helicobacter pylori infection from infancy, adolescence to adulthood.
Optionally, the yolk antibody composition comprises the following components in parts by weight: the four yolk antibodies can effectively prevent and treat stomach problems caused by helicobacter pylori infection, and the four yolk antibodies are compounded and added with other common auxiliary materials to prepare a special functional product for solving gastrointestinal tract disease problems such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
The invention also provides a preparation method of the yolk antibody of the helicobacter pylori hypha ammonia protease, the yolk antibody of the helicobacter pylori outer membrane protein, the yolk antibody of the helicobacter pylori holomyces and the yolk antibody of the helicobacter pylori crushed bacteria, which comprises the following steps: respectively immunizing laying hens with helicobacter pylori mycelium ammonia protease, helicobacter pylori outer membrane protein, helicobacter pylori whole bacteria and helicobacter pylori broken bacteria as immunogens, collecting eggs, adding polyethylene glycol into egg yolk liquid, extracting to obtain crude egg yolk antibody, adding saturated ammonium sulfate water solution, and extracting to obtain pure egg yolk antibody.
Optionally, the specific method for extracting the crude egg yolk antibody by adding polyethylene glycol comprises the following steps:
(a) Adding PBS solution containing polyethylene glycol into egg yolk liquid, mixing, standing, centrifuging, and collecting supernatant;
(b) Adding polyethylene glycol into the supernatant obtained in the step (a), standing, centrifuging, and taking a precipitate;
(c) Dissolving the precipitate obtained in the step (b) by using a PBS solution, filtering by using filter paper, taking filtrate, centrifuging, and taking supernatant;
(d) Adding polyethylene glycol into the supernatant obtained in the step (c), standing, centrifuging, and taking a precipitate to obtain a crude egg yolk antibody product.
and the target antibody is subjected to fractional sedimentation and purification through different polyethylene glycol concentrations.
Optionally, in the step (a), the concentration of the polyethylene glycol in the PBS solution containing polyethylene glycol is 3-4%, preferably 3.5%.
Optionally, in the step (a), the volume of the PBS solution containing polyethylene glycol is 2-4 times of the volume of the egg yolk solution.
Optionally, in the step (b), after the polyethylene glycol is added, the ratio of the volume of the polyethylene glycol in the mixed solution is 10-15%, specifically 10%, 11%, 12%, 13%, 14%, 15%, and the like.
Optionally, in the step (c), after the polyethylene glycol is added, the ratio of the volume of the polyethylene glycol in the mixed solution is 10-15%, specifically 10%, 11%, 12%, 13%, 14%, 15%, and the like.
Optionally, the specific method for extracting the pure yolk antibody from the crude yolk antibody comprises the following steps:
(e) Dissolving the crude egg yolk antibody in a PBS solution, centrifuging, taking supernatant, filtering, and taking filtrate;
(f) dropwise adding a saturated ammonium sulfate aqueous solution into the filtrate obtained in the step (e), uniformly mixing, standing, centrifuging, and taking a precipitate;
(g) and (f) adding a PBS solution and a saturated ammonium sulfate aqueous solution into the precipitate obtained in the step (f), uniformly mixing, standing, and centrifuging to obtain a precipitate, namely the pure egg yolk antibody product.
Optionally, in step (e), the volume of the PBS solution is 0.3 to 1 times, preferably 0.3 to 0.6 times, and more preferably 0.5 times the volume of the egg yolk solution.
Optionally, in the step (f), the volume of the saturated ammonium sulfate aqueous solution is added dropwise to be 0.8-1.2 times, preferably 1 time of the volume of the filtrate.
Optionally, in step (g), the saturated ammonium sulfate is added in a volume of 0.3 to 0.7 times, preferably 0.4 to 0.6 times, and more preferably 0.5 times the volume of the PBS solution.
Optionally, the centrifugation rotation speed of each step is 6000-10000rpm, and the centrifugation time is 10-20 min.
Optionally, the polyethylene glycol is selected from PEG 6000.
The PBS solution in the above steps is phosphate buffer solution, and the pH value is 7.4.
The invention also provides application of the yolk antibody composition in preparing products for preventing and/or treating gastrointestinal tract diseases caused by helicobacter pylori infection.
Alternatively, the product can be a medicine, and also can be food, milk product, beverage and the like, and the yolk antibody composition of the invention can be applied to various products.
Optionally, the gastrointestinal disease comprises gastritis, gastric ulcer, gastric cancer, and the like.
The invention also provides infant milk powder or infant rice powder containing the yolk antibody composition. The yolk antibody milk powder/rice powder for preventing and treating gastrointestinal tract diseases of infants caused by helicobacter pylori infection can be prepared by combining the helicobacter pylori resistant yolk antibody with the helicobacter pylori resistant function with the infant milk powder/rice powder, and the aim of preventing and treating the helicobacter pylori infection can be achieved by eating the normal milk powder/rice powder in the infant period.
the invention also provides milk tea granules containing the egg yolk antibody composition, wherein the helicobacter pylori resistant egg yolk antibody with the function of resisting helicobacter pylori is combined with the common milk tea granules to prepare the egg yolk antibody milk tea granules capable of preventing and treating gastrointestinal diseases of teenagers/adults caused by helicobacter pylori infection.
the invention also provides adult milk powder containing the yolk antibody composition. The yolk antibody milk powder for preventing and treating the gastrointestinal tract diseases of adults caused by helicobacter pylori infection is prepared by combining the helicobacter pylori resistant yolk antibody with the helicobacter pylori resistant function with the adult milk powder, and the purpose of preventing and treating the helicobacter pylori infection can be achieved by ordinary adults by daily eating the milk powder, so that human body touch feeling caused by drug treatment is avoided.
The invention also provides flour containing the yolk antibody composition, which combines the helicobacter pylori resistant yolk antibody with the helicobacter pylori resistant function with common household flour to prepare the yolk antibody functional flour capable of preventing and treating gastrointestinal tract diseases caused by helicobacter pylori infection.
Compared with the prior art, the invention has the following advantages and effects:
(1) The invention utilizes helicobacter pylori and factors related to human body infection as immunogen to prepare yolk antibody protein powder, and the yolk antibody protein powder is added into infant milk powder/rice powder in a compound preparation mode, so that children can prevent and treat helicobacter pylori infection by normally eating the milk powder/rice powder from the infant period, thereby reducing the risk of gastrointestinal diseases of children in later period.
(2) The functional milk tea electuary prepared by adding the composite yolk antibody can ensure the original flavor of milk tea loved by the public, and the yolk antibody prepared by helicobacter pylori is compositely added into the milk tea electuary loved by people (particularly teenagers), so that the gastrointestinal tract problems of gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection can be prevented and treated by pleasantly and actively drinking milk tea in the life of people.
(3) The yolk antibody protein powder is prepared by using helicobacter pylori and factors related to human body infection as immunogens, and is added into adult milk powder in a composite preparation mode, so that people can prevent and treat helicobacter pylori infection by eating the milk powder normally, the risk of gastrointestinal diseases of people can be reduced, and the normal nutritive value of the milk powder drunk by people can be ensured.
(4) The invention uses helicobacter pylori and the factor related to the helicobacter pylori infecting the human body as immunogen to prepare yolk antibody protein powder, and the yolk antibody protein powder is added into common flour in a composite preparation mode to prepare functional flour. People can prevent and treat gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection by eating the flour daily.
(5) The yolk antibody composite preparation adopted by the invention can achieve the purpose of preventing and treating gastrointestinal diseases caused by helicobacter pylori infection, and the yolk antibody is extracted and purified from eggs eaten in daily life and is completely harmless to human bodies.
(6) The invention designs and realizes that the yolk antibody of the mycelium ammonia protease of the helicobacter pylori, the outer membrane protein of the helicobacter pylori, the whole helicobacter pylori and the crushed helicobacter pylori can be used for preparing a better functional health-care product preparation which can not only block the infection of the helicobacter pylori to the human body, but also effectively prevent and treat the diseases related to the helicobacter pylori infection.
Drawings
FIG. 1 is a flow chart showing the process of extracting yolk antibody from yolk liquid in example 1 of the present invention.
FIG. 2 is a graph showing the results of electrophoresis of each yolk antibody in example 1 of the present invention.
FIG. 3 is a graph showing the titer of each yolk antibody in example 1 of the present invention.
FIG. 4 is a graph showing the binding titers of four individual yolk antibodies and the composite antibody to H.pylori in example 1 of the present invention.
Detailed Description
The invention is further described with reference to the drawings and the following detailed description, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
Helicobacter pylori is a gram-negative bacterium that is spiroid, microaerobic, and has very stringent growth requirements. Mainly inhabits the human gastric mucosa and is the main pathogenic factor of chronic active gastritis, peptic ulcer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and gastric cancer. The first successful isolation from biopsy tissue from the gastric mucosa of patients with chronic active gastritis in 1983 is the only microorganism species currently known to survive in the human stomach. 2017, the world health organization international agency for research on cancer lists helicobacter pylori in a category of carcinogens.
There are many virulence factors that lead to disease development by infection with helicobacter pylori, and serine protease (HtrA) is a new secreted virulence factor that has only recently been discovered. It mainly enzymatically cleaves the extracellular domain of E-cadherin, which plays an important role in cell adhesion and carcinogenesis as a membrane surface molecule of mammalian cells.
the outer membrane proteins of helicobacter pylori include lipoproteins, pilin and some adhesion factors. These adhesion factors are closely related to the adhesion colonization of helicobacter pylori, persistent infection and the severity of the disease, and the adhesion is the key to the colonization and pathogenesis of helicobacter pylori. The yolk antibody prepared by taking helicobacter pylori outer membrane protein as an antigen can weaken or even eliminate the adhesion function of the yolk antibody through the binding effect of a specific antigen antibody.
The yolk antibody is extracted from the eggs of experimental animals, and the injury to the animals can be greatly reduced without killing the animals or taking blood and other operations. Moreover, compared with mammals such as rabbits, the experimental animal chicken has the advantages of low feeding cost, large antibody obtaining amount and lasting activity. In addition, the separation and purification steps are simple and easy to operate. IgY has been widely used in many fields including human medicine, animal medicine and other life science fields, including detection and diagnosis of pathogens and haptens, prevention and treatment of gastrointestinal diseases, oral diseases, livestock and aquaculture diseases of humans and animals, antibiotic substitution, biological counterterrorism, organ transplantation, tumor transplantation, food safety and proteomics.
Example 1
1. The yolk antibody is prepared as follows:
Taking helicobacter pylori hypha ammonia protease, helicobacter pylori outer membrane protein, helicobacter pylori whole bacteria and helicobacter pylori broken bacteria as immunogen to immunize laying hens respectively. After three times of immunization, eggs are collected, a polyethylene glycol three-step method is used for extracting the yolk antibody, and then ammonium sulfate two-step method is used for purification. And (3) desalting and sterilizing the purified yolk antibody by using an ultrafiltration method, and finally freeze-drying by using a freeze-drying method to obtain the yolk antibody freeze-dried powder.
The specific process of extracting yolk antibody from yolk liquid is shown in fig. 1, and specifically comprises the following steps:
The yolk antibody of the mycelium amino acid protease of the helicobacter pylori, the yolk antibody of the outer membrane protein of the helicobacter pylori, the yolk antibody of the whole helicobacter pylori and the yolk antibody of the crushed helicobacter pylori for inhibiting the helicobacter pylori are prepared by the following methods:
(1) Preparation of helicobacter pylori hypha ammonia protease: obtained according to the method described in patent (201910356684.1), the final purified protein solution was concentrated to 1 mg/mL. Subpackaging and storing in a refrigerator at-20 deg.C for use.
(2) Preparation of helicobacter pylori outer membrane protein: culturing helicobacter pylori in a large amount under microaerophilic conditions by Columbia blood plates, and collecting wet cells by scraping for 3-5 days. The wet cells thus collected were then subjected to outer membrane protein extraction using a bacterial outer membrane protein extraction kit (from Bebo/BestBio Biotechnology Co., Ltd.) according to the manufacturer's instructions. Quantifying the extracted outer membrane protein by a BCA kit to finally obtain the helicobacter pylori outer membrane protein of 1mg/mL, and subpackaging and storing at-20 ℃ in a refrigerator for later use.
(3) Preparing a whole helicobacter pylori bacterium: resuspending the wet cells obtained in step (2) in phosphate buffer (PBS,0.01mmol, pH 7.4) and adjusting the cell concentration to 3X 10 by McLeod9CFU/mL. Subpackaging the obtained bacterial liquid and storing in a refrigerator at-20 ℃ for later use.
(4) preparation of helicobacter pylori broken bacteria: subjecting the 3 × 10 obtained in the step (3) to9Carrying out ultrasonic treatment on CFU/mL helicobacter pylori whole bacteria for 5min under the condition of 300W power (wherein ultrasonic treatment is suspended for 3s), and obtaining the helicobacter pylori crushed bacteria by a ultrasonic crushing method. Subpackaging and storing in a refrigerator at-20 ℃ for later use.
(5) And (3) immunizing the laying hens for three times by respectively taking the helicobacter pylori mycelium ammonia protease, the helicobacter pylori outer membrane protein, the helicobacter pylori whole bacteria and the helicobacter pylori broken bacteria obtained in the steps as immunogens.
Wherein, for the first immunization, Freund's complete adjuvant and immunogen are mixed according to the volume ratio of 1:1, and the emulsifier is used for immunizing 0.5 ml/egg laying hen after being fully emulsified. The subsequent immunization adopts Freund incomplete adjuvant and immunogen with the volume ratio of 1:1 to be mixed, and the emulsifier is fully emulsified and then used for immunizing 0.5 ml/egg laying hen.
After three times of immunization, eggs are collected, a polyethylene glycol three-step method is used for extracting the yolk antibody, and then ammonium sulfate two-step method is used for purification. The specific operation is shown in fig. 1.
and (3) desalting and sterilizing the purified yolk antibody by using an ultrafiltration method, and finally freeze-drying by using a freeze-drying method to obtain various yolk antibody freeze-dried powders.
2. detection of yolk antibody:
The purified yolk antibody obtained above was subjected to SDS-PAGE and yolk antibody titer detection, and the results are shown in FIG. 2 and FIG. 3.
FIG. 2 is a graph showing the result of electrophoresis of each yolk antibody, in which the Marker M is Marker; the mark 1 is a purified yolk antibody electrophoresis band of the hypromellose protease of the pylorus screw; the mark 2 is a purified helicobacter pylori outer membrane protein yolk antibody electrophoresis band; the mark 3 is a purified helicobacter pylori whole-bacterium egg yolk antibody electrophoresis band; and the mark 4 is an electrophoresis band of the yolk antibody of the helicobacter pylori disrupted bacteria after purification. As can be seen from FIG. 2, each of the yolk antibodies after purification contained the corresponding heavy and light chains and had almost no impurity bands, indicating that the method of this example can achieve a good purification effect.
the specific method for detecting by the enzyme-linked immunosorbent assay comprises the following steps:
First, the whole strain of helicobacter pylori (1X 10) was used8CFU/mL) were coated with 100 μ l of antigen immobilized in 96-well plates per well. Incubating at 37 ℃ for 2 h; then, the PBST is used for washing the plate for 3 times, after the PBST is patted dry by absorbent paper, 30mg/ml of skimmed milk powder is added for sealing 280 microliter/hole, the temperature is 37 ℃, and the time is 1 h; washing the plate with PBST for 3 times, drying with absorbent paper, adding various yolk antibodies, making three multiple holes for each yolk antibody,100 microliters/well, dilution by multiple. After dilution in multiple proportion, incubating the mixture for 1h at 37 ℃; similarly, washing the plate for 3 times, adding 100 microliters/hole of a commercially available enzyme-labeled secondary antibody, incubating for 1h at 37 ℃, washing the plate for 5 times, drying, adding 100 microliters/hole of a TMB color development solution substrate, and incubating for 15min at 37 ℃; after the color development was completed, 50. mu.l/well of stop solution (2% sulfuric acid) was added, and after the addition was completed, the OD450 of each well was measured within 5 min.
The commercially available enzyme-labeled secondary antibody is a commercially available enzyme-labeled secondary antibody: e030180HRP Affinipure Rabbit Anti-Chicken IgY (H + L), origin: united states, brand: earthox, model: e030180-01, company name: shanghai Synxing Biotech Co., Ltd.
FIG. 3 is a graph showing the titer of each yolk antibody obtained by enzyme-linked immunosorbent assay, from which it was found that the titer of H.pylori whole cell yolk antibody (represented by HP in the figure) reached 1: 6400; helicobacter pylori (H.pylori) breaking bacterium egg yolk antibody (P.HP) titer reaches 1: 12800; the titer of the yolk antibody (represented by OMPS in the figure) of the helicobacter pylori outer membrane protein reaches 1: 6400; the titer of yolk antibody (HtrA in the figure) of the helicobacter pylori hyphal ammonia protease reaches 1: 3200; the titer of the yolk antibody obtained by mixing the four yolk antibodies reaches 1:51200, which is far higher than that of any single yolk antibody, so that the titer of the composite yolk antibody is greatly improved, and the yolk antibody can be used for preparing products for preventing and treating gastrointestinal diseases caused by helicobacter pylori infection.
FIG. 4 is a graph showing the binding potency of four separate yolk antibodies and the composite antibody obtained by ELISA and helicobacter pylori, from which it can be found that the dilution factor of the antibody is greater than that of each separate yolk antibody when P/N >2.1, i.e. the binding potency of the composite yolk antibody and helicobacter pylori is much higher than that of any separate yolk antibody, and the yolk antibodies synergize, particularly statistically significant synergy, so that the composite yolk antibody can be used to prepare products for preventing and treating gastrointestinal diseases caused by helicobacter pylori infection. The yolk antibody prepared in the embodiment is used for preparing yolk antibody compounds and composite products thereof in the subsequent embodiments.
Example 2
The embodiment provides a yolk antibody infant milk powder capable of preventing and treating gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection: compounding the following yolk antibodies in parts by weight: 0.3 part of helicobacter pylori hypha amino acid protease egg yolk antibody, 0.25 part of helicobacter pylori outer membrane protein egg yolk antibody, 0.4 part of helicobacter pylori whole bacteria egg yolk antibody and 0.4 part of helicobacter pylori broken bacteria egg yolk antibody; and adding the obtained yolk-antibody complex into infant milk powder to obtain the infant milk powder containing the yolk-antibody complex.
In the embodiment, four yolk antibodies capable of effectively preventing and treating helicobacter pylori infection are compounded to prepare the infant milk powder with special functions, which can be used for solving the problems of gastrointestinal tract diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
Example 3
The embodiment provides a yolk antibody infant rice flour capable of preventing and treating gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection, which comprises the following components in percentage by weight: compounding the following yolk antibodies in parts by weight: 0.3 part of helicobacter pylori hypha amino acid protease egg yolk antibody, 0.3 part of helicobacter pylori outer membrane protein egg yolk antibody, 0.45 part of helicobacter pylori whole-bacterium egg yolk antibody and 0.45 part of helicobacter pylori broken-bacterium egg yolk antibody; and adding the obtained yolk antibody complex into infant rice flour to obtain the infant rice flour containing the yolk antibody complex.
In the embodiment, four yolk antibodies capable of effectively preventing and treating helicobacter pylori infection are compounded to prepare the infant rice flour with special functions, which can be used for solving the problems of gastrointestinal tract diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
Example 4
The embodiment provides a yolk antibody adult milk powder capable of preventing and treating gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection, which comprises the following components in part by weight: compounding the following yolk antibodies in parts by weight: 0.4 parts of yolk antibody of helicobacter pylori hypha ammonia protease, 0.4 parts of yolk antibody of helicobacter pylori outer membrane protein, 0.6 parts of yolk antibody of helicobacter pylori whole bacteria and 0.5 parts of yolk antibody of helicobacter pylori crushed bacteria. Adding the obtained yolk-antibody complex into adult milk powder to obtain adult milk powder containing yolk-antibody complex.
In the embodiment, four yolk antibodies capable of effectively preventing and treating helicobacter pylori infection are compounded to prepare the special-function adult milk powder for solving the problems of gastrointestinal diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
example 5
The embodiment provides a yolk antibody milk tea granule which can prevent and treat gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection: compounding the following yolk antibodies in parts by weight: 0.5 part of yolk antibody of mycelium ammonia protease of helicobacter pylori, 0.5 part of yolk antibody of outer membrane protein of helicobacter pylori, 0.8 part of yolk antibody of whole helicobacter pylori and 0.7 part of yolk antibody of crushed helicobacter pylori. Adding the obtained yolk-antibody complex into adult milk powder to obtain milk tea granule containing the yolk-antibody complex.
in the embodiment, four yolk antibodies capable of effectively preventing and treating helicobacter pylori infection are compounded to prepare the milk tea granules with special functions, which can be used for solving the problems of gastrointestinal tract diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
Example 6
The embodiment provides yolk antibody functional flour capable of preventing and treating gastrointestinal tract problems such as gastritis, gastric ulcer, gastric cancer and the like caused by helicobacter pylori infection, and the yolk antibody functional flour comprises the following components in parts by weight: compounding the following yolk antibodies in parts by weight: 0.2 parts of yolk antibody of mycelium ammonia protease of helicobacter pylori, 0.1 parts of yolk antibody of outer membrane protein of helicobacter pylori, 0.2 parts of yolk antibody of whole helicobacter pylori bacteria and 0.2 parts of yolk antibody of crushed helicobacter pylori bacteria. Adding the obtained yolk antibody complex into adult milk powder to obtain flour containing yolk antibody complex.
In the embodiment, four yolk antibodies capable of effectively preventing and treating helicobacter pylori infection are compounded to prepare the special functional flour capable of solving gastrointestinal tract diseases such as gastritis, gastric ulcer and even gastric cancer caused by helicobacter pylori infection.
In conclusion, the four yolk antibodies are compounded, the binding potency of the obtained compound yolk antibody and helicobacter pylori is far higher than that of any single yolk antibody, the yolk antibody has an obvious effect of resisting helicobacter pylori infection, and the yolk antibody can be further applied to various products and can effectively prevent and treat diseases related to helicobacter pylori infection.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Claims (10)
1. An egg yolk antibody composition comprising: h.pylori hypha ammonia protease egg yolk antibody, H.pylori outer membrane protein egg yolk antibody, H.pylori whole bacteria egg yolk antibody and H.pylori broken bacteria egg yolk antibody.
2. The yolk antibody composition according to claim 1, which comprises the following components in parts by weight: 0.2-0.5 part of helicobacter pylori hypha ammonia protease egg yolk antibody, 0.1-0.5 part of helicobacter pylori outer membrane protein egg yolk antibody, 0.2-0.8 part of helicobacter pylori whole bacteria egg yolk antibody and 0.2-0.7 part of helicobacter pylori broken bacteria egg yolk antibody.
3. Use of a yolk antibody composition according to claim 1 or 2 in the preparation of a product for the prevention and/or treatment of gastrointestinal diseases.
4. The use according to claim 3, wherein the gastrointestinal disorder is caused by helicobacter pylori infection.
5. the use according to claim 3, wherein the gastrointestinal disorders comprise gastritis, gastric ulcers, gastric cancer.
6. An infant milk powder or infant rice powder comprising the yolk antibody composition of claim 1 or 2.
7. A milk tea granule containing the yolk antibody composition of claim 1 or 2.
8. An adult milk powder comprising the yolk antibody composition of claim 1 or 2.
9. Flour containing the yolk antibody composition of claim 1 or 2.
10. A method for producing the yolk antibody against the serine protease derived from helicobacter pylori, the yolk antibody against outer membrane protein of helicobacter pylori, the yolk antibody against helicobacter pylori whole bacteria, the yolk antibody against helicobacter pylori disrupted bacteria according to claim 1 or 2, comprising: respectively immunizing laying hens with helicobacter pylori mycelium ammonia protease, helicobacter pylori outer membrane protein, helicobacter pylori whole bacteria and helicobacter pylori broken bacteria as immunogens, collecting eggs, adding polyethylene glycol into egg yolk liquid, extracting to obtain crude egg yolk antibody, adding saturated ammonium sulfate water solution, and extracting to obtain pure egg yolk antibody.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910819357.5A CN110559436A (en) | 2019-08-31 | 2019-08-31 | Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910819357.5A CN110559436A (en) | 2019-08-31 | 2019-08-31 | Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110559436A true CN110559436A (en) | 2019-12-13 |
Family
ID=68777184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910819357.5A Pending CN110559436A (en) | 2019-08-31 | 2019-08-31 | Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110559436A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115553469A (en) * | 2022-09-27 | 2023-01-03 | 六安益普罗科技有限公司 | Stomach mucosa adhesion probiotic slow-release microspheres, preparation method and food for preparing anti-helicobacter pylori or relieving gastritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180197A (en) * | 1997-09-04 | 1999-03-26 | Kyodo Nyugyo Kk | Preventive and therapeutic agent against helicobacter pylori and relating infections |
| CN108531468A (en) * | 2018-02-24 | 2018-09-14 | 广东工业大学 | Encode gene, Yolk antibody and the application of recombinant helicobacterpylori serine protease |
| CN108794628A (en) * | 2018-05-28 | 2018-11-13 | 广东工业大学 | A kind of Yolk antibody preparation method and application of anti-helicobacter pylori |
-
2019
- 2019-08-31 CN CN201910819357.5A patent/CN110559436A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1180197A (en) * | 1997-09-04 | 1999-03-26 | Kyodo Nyugyo Kk | Preventive and therapeutic agent against helicobacter pylori and relating infections |
| CN108531468A (en) * | 2018-02-24 | 2018-09-14 | 广东工业大学 | Encode gene, Yolk antibody and the application of recombinant helicobacterpylori serine protease |
| CN108794628A (en) * | 2018-05-28 | 2018-11-13 | 广东工业大学 | A kind of Yolk antibody preparation method and application of anti-helicobacter pylori |
Non-Patent Citations (2)
| Title |
|---|
| 文冰等: "特异性抗幽门螺杆菌IgY的制备和活性测定", 《南昌大学学报(医学版)》 * |
| 韩飞等: "HP1188-IgY对感染幽门螺杆菌BALB/c小鼠的治疗作用", 《中国病理生理杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115553469A (en) * | 2022-09-27 | 2023-01-03 | 六安益普罗科技有限公司 | Stomach mucosa adhesion probiotic slow-release microspheres, preparation method and food for preparing anti-helicobacter pylori or relieving gastritis |
| CN115553469B (en) * | 2022-09-27 | 2023-10-03 | 六安益普罗科技有限公司 | Stomach mucosa-adhered probiotic slow-release microsphere, preparation method and medicine for preparing helicobacter pylori resisting or stomach mucositis relieving medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997020577A1 (en) | Improved therapeutic formulation and method | |
| CA2267421A1 (en) | Oral administration of chicken yolk antibodies to treat disease | |
| JPH10287585A (en) | Preventing agent and therapeutic agent for gastritis, gastric ulcer and duodenal ulcer | |
| EP2500034A1 (en) | Therapeutic agent for psoriasis or atopic dermatitis | |
| KR102047784B1 (en) | Manufacturing method of Immunoglobulin Y for preventing or treating calf digestive diseases, and Immunoglobulin Y thereby and the use thereof | |
| JPH0253737A (en) | Production of polyfunctional specific antibody | |
| CA2437095A1 (en) | Methods and compositions for modulating the immune system of animals | |
| CN110559436A (en) | Yolk antibody composition and application thereof in preparation of products for preventing and treating gastrointestinal diseases | |
| CN109400705A (en) | A kind of anti-helicobacter pylori duck Yolk antibody and preparation method thereof | |
| CN109453372A (en) | A kind of additive of the Yolk antibody of duck containing anti-helicobacter pylori | |
| KR20110097960A (en) | Method for producing comprehensive anti-surface antibody wherein the antigen used is a microorganism fixed by a protein crosslinking and fixation reagent | |
| EP1589995B1 (en) | Use of avian antibodies | |
| CN1634989A (en) | Bacillus coli resisting chicken yolk antibody, its preparation and use | |
| KR19980081625A (en) | Prevention and treatment of infections caused by intestinal hemorrhagic E. coli | |
| CN114470198B (en) | IgY spray of SARS-CoV-2 egg yolk neutralization antibody for preventing and treating new coronal pneumonia | |
| KR100364198B1 (en) | An Improved Method for Inducing IgY to Helicobacter pylori and an Egg Prepared by Using the Same | |
| JP2004135669A6 (en) | A lactic acid bacterial strain named Pediococcus pentosaceus CBT-8, which produces an antibacterial active substance that suppresses the growth of Helicobacter pylori and Listeria monocytogenes, is used as an antibacterial bacterium. Method for producing antibacterial substance having bioactive agent and method for utilizing antibacterial substance for functional foods and pharmaceuticals | |
| JP2968095B2 (en) | Immunoglobulin-containing composition | |
| Karsner et al. | The principles of immunology | |
| CN112625126A (en) | anti-Hafnia alvei yolk antibody and preparation method and application thereof | |
| KR20040083748A (en) | The method for production of spectific yolk antibody containing anti-helicobacter pylori IgY, anti-salmonella enteritidis IgY and anti-staphylococcus aureus IgY and have the anti-enzyme with anti-enzyme. | |
| CN101040632B (en) | Milk product with specific immunity of anti-enterobacter sakazakii and the preparing method thereof | |
| WO2020139308A1 (en) | Inactivated staphylococcal liquid vaccine | |
| EP0996423B1 (en) | A method for producing jelly sweets which contain antibodies | |
| JP2935193B2 (en) | Manufacturing method of therapeutic agent for rotavirus infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210319 Address after: 102200 9, building 2, 20 Xiguan Road, Chengbei street, Changping District, Beijing Applicant after: Beijing Yucheng Health Technology Co.,Ltd. Address before: 511404 No.100, Waihuan West Road, University Town, Panyu District, Guangzhou City, Guangdong Province Applicant before: GUANGDONG University OF TECHNOLOGY |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191213 |